Merck Kgaa Dm 5 (MKGAF) 113.0000 $MKGAF
HyperAcute Pancreas Will Go To The Wire
EP Vantage - at Seeking Alpha - Wed May 13, 11:50AM CDT
With no call for an early stop to the Impress trial of NewLink Genetics ' (NASDAQ: NLNK ) HyperAcute Pancreas in second-line pancreatic cancer, investors will be left waiting until next year for the results of this binary event. Expectations on...
MACK: 12.66 (+0.34), INCY: 106.86 (+0.08), NLNK: 39.69 (+1.57), THLD: 3.94 (+0.02)
Threshold Pharma's evofosfamide Fast Track'd for pancreatic cancer; shares rise
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:53AM CDT
THLD: 3.94 (+0.02)
Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:50PM CDT
Merck KGaA (MKGAF) and Pfizer Inc. (PFE) announced the commencement of a phase III study on avelumab in comparison with Taxotere for non-small cell lung cancer.
SHPG: 254.45 (+3.99), PFE: 33.99 (+0.05), HZNP: 29.03 (+0.63)
Bristol-Myers to Transfer Certain Erbitux Rights to Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 3:45PM CDT
Bristol-Myers announced its intention to transfer its rights to Erbitux in North America to Eli Lilly and Company.
VRX: 224.63 (+1.81), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19)
Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:30AM CDT
Merck KGaA (MKGAF) and Pfizer will have signed an agreement to co-promote Xalkori in the U.S., Canada, five countries in the EU, Japan, China and Turkey for lung cancer.
CYTK: 5.96 (-0.06), PFE: 33.99 (+0.05)
Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 5:26PM CDT
Intrexon Corporation (XON) and Merck KGaA announced the signing of an agreement to develop and commercialize cancer therapies based on CAR-T platform.
CYTK: 5.96 (-0.06), ZIOP: 9.17 (-0.17), XON: 40.08 (-0.90)
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 391.24 (-3.11), ACT: 296.60 (-0.86), VRX: 224.63 (+1.81), PCYC: 255.42 (-0.50), OSIR: 17.29 (-0.18), ACOR: 30.04 (+0.14), HSP: 88.10 (-0.08), AGN: 240.22 (+2.88), MDVN: 122.90 (-0.47), ESRX: 87.37 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ARNA: 4.25 (unch), REGN: 489.01 (-2.42), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), AMGN: 162.36 (+0.38), MYL: 70.67 (-0.86), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ALKS: 60.00 (unch), MNKD: 3.99 (+0.36), OREX: 5.01 (unch), NVO: 56.75 (+0.06), ISIS: 62.55 (+0.10), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), PBYI: 177.01 (+6.34), NVS: 103.75 (-0.15)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 391.24 (-3.11), ACT: 296.60 (-0.86), VRX: 224.63 (+1.81), PCYC: 255.42 (-0.50), OSIR: 17.29 (-0.18), ACOR: 30.04 (+0.14), HSP: 88.10 (-0.08), AGN: 240.22 (+2.88), MDVN: 122.90 (-0.47), ESRX: 87.37 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ARNA: 4.25 (unch), REGN: 489.01 (-2.42), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), AMGN: 162.36 (+0.38), MYL: 70.67 (-0.86), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ALKS: 60.00 (unch), MNKD: 3.99 (+0.36), OREX: 5.01 (unch), NVO: 56.75 (+0.06), ISIS: 62.55 (+0.10), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), PBYI: 177.01 (+6.34), NVS: 103.75 (-0.15)
Merck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 10, 4:16PM CDT
Merck KGaA (MKGAF) announced an amendment to its agreement with Opexa for the development and marketing of Opexa's investigational compound, Tcelna.
LCI: 52.60 (-0.73), BIIB: 391.24 (-3.11), OPXA: 0.38 (-0.01), NVS: 103.75 (-0.15)
Biosimilars the Way Forward: Companies in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Mar 09, 8:38AM CDT
With the FDA approving the first biosimilar in the U.S., this is a market that will remain in focus in the coming years as several hot-selling blockbuster biologics lose exclusivity.
BIIB: 391.24 (-3.11), ACT: 296.60 (-0.86), ESRX: 87.37 (-0.09), MRK: 60.23 (+0.45), PFE: 33.99 (+0.05), MYL: 70.67 (-0.86), AMGN: 162.36 (+0.38), HSP: 88.10 (-0.08), NVS: 103.75 (-0.15)
Merck KGaA's Q4 Net Income Flat Y/Y, Provides 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:40AM CST
Merck KGaA's (MKGAF) net income during the fourth quarter of 2014 came in at 280 million euros compared with 280.6 million euros in the year-ago period.
PFE: 33.99 (+0.05), SLXP: 172.96 (+0.15), SCMP: 15.94 (-0.01)
Merck KGaA to Gain Full Marketing Rights to Erbitux in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 16, 2:10PM CST
Merck KGaA (MKGAF) announced that it will acquire full responsibility for the promotion of Erbitux from Bristol-Myers in Japan.
LCI: 52.60 (-0.73), SCMP: 15.94 (-0.01), BMY: 67.64 (+0.19)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.75 (+0.20), SCMP: 15.94 (-0.01), BIOD: 1.13 (unch)
Is Sigma-Aldrich (SIAL) a Sell After Its Buyout Proposition? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 11:50AM CST
Zacks Investment Research has downgraded Sigma-Aldrich (SIAL) to a Zacks Rank #4 (Sell).
ROC: 79.20 (+0.33), NL: 7.26 (-0.18), SIAL: 139.08 (+0.09)
Germany's Merck sticking with consumer healthcare business
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 9:35AM CST
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.77 (-0.40), BIB: 168.53 (+0.54), INCY: 106.86 (+0.08), PFE: 33.99 (+0.05), IBB: 355.61 (+0.02), DRGS: 60.89 (unch), BIND: 6.24 (unch), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ONTY: 2.43 (+0.41), ECYT: 6.02 (unch), BIS: 31.35 (-0.07), CLVS: 92.74 (-7.66), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), ARIA: 8.89 (-0.02), IRY: 53.95 (+0.16), IXJ: 110.79 (+0.24), FPRX: 21.11 (-0.06)
Merck Collaboration Rules Out AstraZeneca Acquisition--For Now
Anyoption - at Seeking Alpha - Fri Nov 21, 2:06PM CST
PFE: 33.99 (+0.05), AZN: 69.29 (-0.81)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 296.60 (-0.86), QLTI: 3.72 (+0.03), VRX: 224.63 (+1.81), AGN: 240.22 (+2.88), SHPG: 254.45 (+3.99), AUXL: 36.47 (-0.06), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), MYL: 70.67 (-0.86), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), BMY: 67.64 (+0.19), ACHN: 9.57 (+0.05), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), ICPT: 306.23 (-0.84), TEVA: 60.23 (-0.99), NVS: 103.75 (-0.15)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 296.60 (-0.86), QLTI: 3.72 (+0.03), VRX: 224.63 (+1.81), AGN: 240.22 (+2.88), SHPG: 254.45 (+3.99), AUXL: 36.47 (-0.06), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), MYL: 70.67 (-0.86), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), BMY: 67.64 (+0.19), ACHN: 9.57 (+0.05), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), ICPT: 306.23 (-0.84), TEVA: 60.23 (-0.99), NVS: 103.75 (-0.15)
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:15PM CST
Merck KGaA (MKGAF) inked a deal with Pfizer to co-develop and co-commercialize MSB0010718C as a potential treatment for multiple types of tumor.
LCI: 52.60 (-0.73), PFE: 33.99 (+0.05), BIOD: 1.13 (unch)
HyperAcute Pancreas Will Go To The Wire
EP Vantage - at Seeking Alpha - Wed May 13, 11:50AM CDT
With no call for an early stop to the Impress trial of NewLink Genetics ' (NASDAQ: NLNK ) HyperAcute Pancreas in second-line pancreatic cancer, investors will be left waiting until next year for the results of this binary event. Expectations on...
MACK: 12.66 (+0.34), INCY: 106.86 (+0.08), NLNK: 39.69 (+1.57), THLD: 3.94 (+0.02)
Threshold Pharma's evofosfamide Fast Track'd for pancreatic cancer; shares rise
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:53AM CDT
THLD: 3.94 (+0.02)
Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:50PM CDT
Merck KGaA (MKGAF) and Pfizer Inc. (PFE) announced the commencement of a phase III study on avelumab in comparison with Taxotere for non-small cell lung cancer.
SHPG: 254.45 (+3.99), PFE: 33.99 (+0.05), HZNP: 29.03 (+0.63)
Bristol-Myers to Transfer Certain Erbitux Rights to Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 3:45PM CDT
Bristol-Myers announced its intention to transfer its rights to Erbitux in North America to Eli Lilly and Company.
VRX: 224.63 (+1.81), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19)
Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:30AM CDT
Merck KGaA (MKGAF) and Pfizer will have signed an agreement to co-promote Xalkori in the U.S., Canada, five countries in the EU, Japan, China and Turkey for lung cancer.
CYTK: 5.96 (-0.06), PFE: 33.99 (+0.05)
Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 5:26PM CDT
Intrexon Corporation (XON) and Merck KGaA announced the signing of an agreement to develop and commercialize cancer therapies based on CAR-T platform.
CYTK: 5.96 (-0.06), ZIOP: 9.17 (-0.17), XON: 40.08 (-0.90)
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 391.24 (-3.11), ACT: 296.60 (-0.86), VRX: 224.63 (+1.81), PCYC: 255.42 (-0.50), OSIR: 17.29 (-0.18), ACOR: 30.04 (+0.14), HSP: 88.10 (-0.08), AGN: 240.22 (+2.88), MDVN: 122.90 (-0.47), ESRX: 87.37 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ARNA: 4.25 (unch), REGN: 489.01 (-2.42), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), AMGN: 162.36 (+0.38), MYL: 70.67 (-0.86), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ALKS: 60.00 (unch), MNKD: 3.99 (+0.36), OREX: 5.01 (unch), NVO: 56.75 (+0.06), ISIS: 62.55 (+0.10), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), PBYI: 177.01 (+6.34), NVS: 103.75 (-0.15)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 391.24 (-3.11), ACT: 296.60 (-0.86), VRX: 224.63 (+1.81), PCYC: 255.42 (-0.50), OSIR: 17.29 (-0.18), ACOR: 30.04 (+0.14), HSP: 88.10 (-0.08), AGN: 240.22 (+2.88), MDVN: 122.90 (-0.47), ESRX: 87.37 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ARNA: 4.25 (unch), REGN: 489.01 (-2.42), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), AMGN: 162.36 (+0.38), MYL: 70.67 (-0.86), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ALKS: 60.00 (unch), MNKD: 3.99 (+0.36), OREX: 5.01 (unch), NVO: 56.75 (+0.06), ISIS: 62.55 (+0.10), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), PBYI: 177.01 (+6.34), NVS: 103.75 (-0.15)
Merck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 10, 4:16PM CDT
Merck KGaA (MKGAF) announced an amendment to its agreement with Opexa for the development and marketing of Opexa's investigational compound, Tcelna.
LCI: 52.60 (-0.73), BIIB: 391.24 (-3.11), OPXA: 0.38 (-0.01), NVS: 103.75 (-0.15)
Biosimilars the Way Forward: Companies in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Mar 09, 8:38AM CDT
With the FDA approving the first biosimilar in the U.S., this is a market that will remain in focus in the coming years as several hot-selling blockbuster biologics lose exclusivity.
BIIB: 391.24 (-3.11), ACT: 296.60 (-0.86), ESRX: 87.37 (-0.09), MRK: 60.23 (+0.45), PFE: 33.99 (+0.05), MYL: 70.67 (-0.86), AMGN: 162.36 (+0.38), HSP: 88.10 (-0.08), NVS: 103.75 (-0.15)
Merck KGaA's Q4 Net Income Flat Y/Y, Provides 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:40AM CST
Merck KGaA's (MKGAF) net income during the fourth quarter of 2014 came in at 280 million euros compared with 280.6 million euros in the year-ago period.
PFE: 33.99 (+0.05), SLXP: 172.96 (+0.15), SCMP: 15.94 (-0.01)
Merck KGaA to Gain Full Marketing Rights to Erbitux in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 16, 2:10PM CST
Merck KGaA (MKGAF) announced that it will acquire full responsibility for the promotion of Erbitux from Bristol-Myers in Japan.
LCI: 52.60 (-0.73), SCMP: 15.94 (-0.01), BMY: 67.64 (+0.19)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.75 (+0.20), SCMP: 15.94 (-0.01), BIOD: 1.13 (unch)
Is Sigma-Aldrich (SIAL) a Sell After Its Buyout Proposition? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 11:50AM CST
Zacks Investment Research has downgraded Sigma-Aldrich (SIAL) to a Zacks Rank #4 (Sell).
ROC: 79.20 (+0.33), NL: 7.26 (-0.18), SIAL: 139.08 (+0.09)
Germany's Merck sticking with consumer healthcare business
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 9:35AM CST
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.77 (-0.40), BIB: 168.53 (+0.54), INCY: 106.86 (+0.08), PFE: 33.99 (+0.05), IBB: 355.61 (+0.02), DRGS: 60.89 (unch), BIND: 6.24 (unch), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ONTY: 2.43 (+0.41), ECYT: 6.02 (unch), BIS: 31.35 (-0.07), CLVS: 92.74 (-7.66), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), ARIA: 8.89 (-0.02), IRY: 53.95 (+0.16), IXJ: 110.79 (+0.24), FPRX: 21.11 (-0.06)
Merck Collaboration Rules Out AstraZeneca Acquisition--For Now
Anyoption - at Seeking Alpha - Fri Nov 21, 2:06PM CST
PFE: 33.99 (+0.05), AZN: 69.29 (-0.81)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 296.60 (-0.86), QLTI: 3.72 (+0.03), VRX: 224.63 (+1.81), AGN: 240.22 (+2.88), SHPG: 254.45 (+3.99), AUXL: 36.47 (-0.06), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), MYL: 70.67 (-0.86), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), BMY: 67.64 (+0.19), ACHN: 9.57 (+0.05), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), ICPT: 306.23 (-0.84), TEVA: 60.23 (-0.99), NVS: 103.75 (-0.15)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 296.60 (-0.86), QLTI: 3.72 (+0.03), VRX: 224.63 (+1.81), AGN: 240.22 (+2.88), SHPG: 254.45 (+3.99), AUXL: 36.47 (-0.06), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), MYL: 70.67 (-0.86), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), BMY: 67.64 (+0.19), ACHN: 9.57 (+0.05), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), ICPT: 306.23 (-0.84), TEVA: 60.23 (-0.99), NVS: 103.75 (-0.15)
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:15PM CST
Merck KGaA (MKGAF) inked a deal with Pfizer to co-develop and co-commercialize MSB0010718C as a potential treatment for multiple types of tumor.
LCI: 52.60 (-0.73), PFE: 33.99 (+0.05), BIOD: 1.13 (unch)
